Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

Bird flu cases are still rising in the U.S. as the virus continues to devastate poultry farms. More than 145 million chickens ...

Sneezing, fever, chills, vomiting, coughing — it’s not just one virus wreaking havoc this winter; it’s a combination of four ...

The US Department of Health and Human Services awarded Moderna $590 million to continue developing a vaccine to protect against bird flu.

Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in ...

Moderna is developing an mRNA-based vaccine for norovirus, now in Phase 3 trials, with hopes of approval by 2026 to combat the highly contagious stomach virus.

A surge in respiratory illness is typical for this time of year, and the simultaneous outbreak of highly contagious norovirus is piling on to the public health risk. Commonly known as stomach flu, ...

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

Moderna is testing a norovirus vaccine in a phase three trial. Results could be available as soon as this year.

The Department of Health and Human Services (HHS) will award roughly $590 million to Moderna to accelerate the development of ...

RNA vaccine developer Moderna (MRNA) is climbing nearly 5% in early trading today after it was awarded about $590 million by the U.S.

The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...